Abstract
Ambroxol preferentially inhibits tetrodotoxin (TTX)-resistant (TTX-R), rather than TTX-sensitive (TTX-S), sodium channel α-subunit. Changes in sodium channel activity in sensory nerves have been suggested to be involved in the aberrant sensory perception in diabetes mellitus. The present study examined the effect of ambroxol on thermal hyperalgesia in diabetic mice. Treatment with ambroxol (3-30 mg/kg, p.o.) dose-dependently increased the tail-flick latency in diabetic, but not non-diabetic mice. This prolongation in diabetic mice was attenuated by pretreatment with fenvalerate (0.01 µg, i.t.). Immunoblot experiments demonstrated significant increases in the expression of TTX-S Nav1.7 and TTX-R Nav1.9 and decreases in the expression of TTX-S Nav1.6 and TTX-R Nav1.8 in the dorsal root ganglion (DRG) of diabetic mice. The expression of mRNA levels of Nav1.6, Nav1.7, Nav1.8 and Nav1.9 was not changed in the DRG of diabetic mice. These results suggest that ambroxol may be of therapeutic value against hyperalgesia in diabetes mellitus. Our present results further suggest that Nav1.9 may be an attractive target for treating the symptoms of painful diabetic neuropathies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
